Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes

Andrew Loblaw, Patrick Cheung, Laura D'Alimonte, Andrea Deabreu, Alexandre Mamedov, Liying Zhang, Colin Tang, Harvey Quon, Suneil Jain, Geordi Pang, Robert Nam

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Biological dose escalation through stereotactic ablative radiotherapy (SABR) holds promise of improved patient convenience, system capacity and tumor control with decreased cost and side effects. The objectives are to report the toxicities, biochemical and pathologic outcomes of this prospective study.
Original languageEnglish
Pages (from-to)153-158
JournalRadiotherapy and Oncology
Volume107
Issue number2
Early online date03 May 2013
DOIs
Publication statusPublished - May 2013

Bibliographical note

Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Fingerprint Dive into the research topics of 'Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes'. Together they form a unique fingerprint.

  • Cite this

    Loblaw, A., Cheung, P., D'Alimonte, L., Deabreu, A., Mamedov, A., Zhang, L., Tang, C., Quon, H., Jain, S., Pang, G., & Nam, R. (2013). Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes. Radiotherapy and Oncology, 107(2), 153-158. https://doi.org/10.1016/j.radonc.2013.03.022